Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
In recent trading, Intellia Therapeutics Inc (NTLA) stock price has shown some volatility, fluctuating -16.50% over the last five trades and -33.41% over the past 30 trades. This represents a notable ...
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
3d
Cathie Wood is defending her fraught ARK Innovation exchange traded fund following a rocky stretch. "We have a volatile fund, ...
On Wednesday, Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $16.11 which represents a decrease of $-0.54 or -3.24% from the prior close of $16.65. The stock opened at $16.8 ...
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback